Delving into the Latest Updates on Glycyrrhetinic Acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Enoxolone (INN), Glycyrrhetic Acid, Glycyrrhetinic acid (JAN)

+ [5]

Target

11β-HSD1

Action

inhibitors

Mechanism

11β-HSD1 inhibitors(Corticosteroid 11-beta-dehydrogenase isozyme 1 inhibitors)

Therapeutic Areas

Skin and Musculoskeletal DiseasesDigestive System Disorders

Active Indication

EczemaNeurodermatitisPruritus+ [1]

Inactive Indication-

Originator Organization

Minophagen Pharmaceutical Co. Ltd.

Active Organization

Mayado Pharmaceutical Co., Ltd.

Nanjing University of Chinese Medicine

Miyarisan Pharmaceutical Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (19 Aug 1965),

EczemaNeurodermatitisPruritus

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC30H46O4

InChIKeyMPDGHEJMBKOTSU-YKLVYJNSSA-N

CAS Registry471-53-4

This research study will compare the effect of test product #1 (containing a probiotic with the Galacto-OligoSaccharides fiber. GOS) and test product #2 (containing a probiotic without the GOS fiber) to understand how they can contribute to healthy digestion in toddlers between the age of 24 - 36 months. The hypothesis is that L. reuteri from TEST#1 will demonstrate an improved survival in the GIT of toddlers compared to that of TEST#2.
This study is a single-centre, randomized, double-blind, comparator-controlled, parallel group study. The study will be conducted at the Clinical Innovation Lab (CIL) at Nestlé Research.

Start Date30 Jun 2022

Sponsor / Collaborator

Société des Produits Nestlé SA

ISRCTN31328643

/ CompletedNot Applicable

A comprehensive study of the efficacy and safety of Licochalcone A , Glycyrrhetinic acid and L-Carnitine containing sun block in the management of acne and post acne pigmentation among Malaysian patients : A randomized, double blinded, comparator controlled trial

Start Date01 Mar 2022

Sponsor / Collaborator-

100 Clinical Results associated with Glycyrrhetinic Acid

Login to view more data

100 Translational Medicine associated with Glycyrrhetinic Acid

Login to view more data

100 Patents (Medical) associated with Glycyrrhetinic Acid

Login to view more data

4,225

Literatures (Medical) associated with Glycyrrhetinic Acid

01 Jan 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Insights on the synergistic effects of glycyrrhetinic acid and isoliquiritigenin on HMGB1-induced inflammation by multi-spectroscopic and molecular docking studies

Article

Author: Yi, Shaoyan ; Ge, Haixia ; Shen, Pingping ; Raj, Richa ; Zhang, Jian ; Jiang, Xuewa

Chronic low-grade inflammation, driven by elevated levels of circulating high mobility group box1 (HMGB1), plays a crucial role in the pathogenesis of multiple chronic diseases. Glycyrrhetinic acid (GA) and isoliquiritigenin (ISL) are representative metabolites in licorice, exhibit potent regulatory effects on HMGB1-mediated chronic inflammation. In this research, we investigated the interactions of GA and ISL with HMGB1 using multi-spectroscopy, surface plasmon resonance (SPR), and molecular docking. Fluorescence spectroscopy revealed that GA or ISL binds to HMGB1, leading to static fluorescence quenching of the protein. Additionally, the binding of GA or ISL altered the microenvironment of tryptophan and decreased the α-helix content of HMGB1 to varying extents. Dynamic light scattering (DLS) showed that GA induced aggregation of the HMGB1 complex into large particles, while ISL reduced the particle size of HMGB1. SPR analysis confirmed that GA and ISL bound reversibly to HMGB1 with K_d values of 53.0 ± 3.6 and 16.3 ± 0.5 μM, respectively. Molecular docking further elucidated the binding modes and sites of GA and ISL on HMGB1, showing that GA binds to the B-box and ISL binds to the A-box of HMGB1, with hydrogen bonding and hydrophobic interactions as the primary driving forces. Isobologram analysis demonstrated that the combination of GA and ISL exhibited a significant synergistic inhibitory effect on HMGB1-induced inflammation on RAW264.7 cells, with an optimal combination ratio of 1:1. This study reveals that GA and ISL synergistically exert anti-inflammatory effect by modulating HMGB1 conformation, offering new insights into licorice extracts for preventing chronic inflammatory diseases.

31 Dec 2025·ANNALS OF MEDICINE

Exploring the key ingredients and mechanisms of Banxia Xiexin decoction for the treatment of polycystic ovary syndrome based on network pharmacology and experimental validation

Article

Author: Wang, Mingming ; Zhang, Yingying ; Huang, Jing ; Mprah, Richard ; Hai, Bai

PURPOSE:

This study aimed to investigate the key bioactive constituents and polypharmacological mechanisms of Banxia Xiexin Decoction (BXD) against polycystic ovary syndrome (PCOS) through integrated network pharmacology and experimental validation.

METHODS:

Network pharmacology was used to determine the key ingredients, potential targets and signaling pathways. 3-week-old female mice were injected subcutaneously with DHEA (6mg/100g body weight) daily to construct a PCOS model and administered different doses BXD and its key ingredients for intervention. Ovarian pathology, vaginal smears, oxidative stress-related indicators, and hub genes were tested to evaluate its therapeutic effects.

RESULTS:

We identified 3 key ingredients and 99 potential targets for BXD treatment of PCOS. Biological functions of these targets were mainly enriched in oxidative stress, hormone response and apoptosis. KEGG analysis showed they were mainly involved in signaling pathways such as PI3K-AKT, MAPK, HIF-1 and IL17. By PPI and algorithmic analysis, we identified 8 hub genes, 5 of which (JUN, MAPK1, MAPK3, FOS, TP53) were related to oxidative stress. Further analysis indicated that quercetin, glycyrrhetinic acid A and naringenin are the three key ingredients of BXD, and they have superior binding effects on the hub genes. Animal experiments demonstrated that BXD and its three key ingredients significantly ameliorated the PCOS symptoms, oxidative stress-related indicators and the expression of hub genes.

CONCLUSIONS:

Five oxidative stress-related hub targets of BXD for PCOS were identified, including FOS, JUN, MAPK3, TP53 and HSP90AA1, while three key ingredients of BXD, quercetin, glycyrrhetinic acid A and naringenin, were uncovered.

01 Nov 2025·FOOD CHEMISTRY

pH-driven construction of lactoferrin nanoparticles to enhance antimicrobial activity of glycyrrhetinic acid with charge-designable properties

Article

Author: Rao, Yuan ; Li, Yishan ; Yan, Yucheng ; Yuan, Qipeng ; Liang, Hao

Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat to food safety, emphasizing the urgent necessity for innovative antimicrobial strategies. Glycyrrhetinic acid (GA) has demonstrated promising anti-MRSA potential; however, its poor water solubility limits its application in the food industry. To improve the solubility and anti-MRSA efficacy of GA, Glycyrrhetinic acid-lactoferrin nanoparticles (GA-LF NPs) were developed by the pH-driven method. The resultant nanoparticles significantly reduced the minimum inhibitory concentration (MIC) of GA to 29.38 μg/mL, and the formation of biofilms to 27.04 %. These nanoparticles exhibited surface charge-dependent antibiofilm activity. When modified to carry a positive surface charge, the GA-LF NPs achieved a markedly higher biofilm inhibition ratio of 7.31 %. Notably, GA-LF NPs maintained biocompatibility with beneficial probiotic strains such as Lactococcus lactis (L. lactis) and Lactobacillus acidophilus (L. acidophilus). This charge-adjustable, food-sourced nanoparticles system offers a promising targeted strategy against MRSA contamination, while preserving the microbial balance in food systems.

100 Deals associated with Glycyrrhetinic Acid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00156	Glycyrrhetinic Acid	D03AX10	DB13089

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Eczema	Japan	Mayado Pharmaceutical Co., Ltd.	19 Aug 1965
Neurodermatitis	Japan	Mayado Pharmaceutical Co., Ltd.	19 Aug 1965
Pruritus	Japan	Mayado Pharmaceutical Co., Ltd.	19 Aug 1965

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stomach Diseases	Preclinical	China	Nanjing University of Chinese Medicine	01 Jul 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01576783 (CTgov)	Phase 4	Obstetric Labor, Premature	377	Arachidonic Acid+Docosahexaenoic Acid (Docosahexaenoic Acid + Arachidonic Acid)	whcmsmtrfm(mpscteagmd) = wneyzlpfsd tfuyxoepnf (uhjszmbhbq, 5.2) View more	-	24 May 2019
				Placebo (Placebo)	whcmsmtrfm(mpscteagmd) = veavbyzxtv tfuyxoepnf (uhjszmbhbq, 4.4) View more
NCT01661764 (CTgov)	Phase 2	Adenomatous Polyposis Coli	141	Eicosapentanoic acid+docosahexanoic acid (rs174535 (GG), Fish Oil Supplements)	fsdqrjbrhk(jpiqvgjkwh) = tibmlmcqzb kxgaqijmac (rbdbgftjvk, 6.8) View more	-	08 May 2018
				Oleic Acid (rs174535 (GG), Placebo)	fsdqrjbrhk(jpiqvgjkwh) = phmbkgiyfs kxgaqijmac (rbdbgftjvk, 7.6) View more